NEW YORK, May 24 - Proteomics startup ActivX Biosciences has appointed David Campbell, formerly director of discovery chemistry at Bayer, to the position of vice president of chemistry, the company said Thursday.
At ActivX Campbell will be responsible for overseeing all chemistry programs at the company.
Prior to working for Bayer, where he directed target discovery research in cancer and obesity, Campbell served as director of chemistry at Affymax Research Institute, a company with expertise in combinatorial chemistry and high-throughput screening.
"David Campbell is one of the new breed of young leaders in pharmaceutical chemistry," John Kozarich, ActivX's president and chief scientific officer, said in a statement. "His considerable accomplishments in the arenas of biotechnology and big pharma give him a unique perspective on discovery at the interface of chemistry and biology. He will be a major force in the application of ActivX chemistry to proteomics."ActivX was founded last year by Robert Hillman, the company's CEO; Ben Cravatt, a faculty member at the Scripps Research Institute; and Jeffrey Smith, a member of the Burnham Institute. The company is developing a high-throughput platform for discovering medically-relevant proteins.